TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05694390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of sterile transparent film dressing
Description: The nurses in the unit were trained by the charge nurse of the clinic on catheter-related complications (infiltration, extravasation, phlebitis, and occlusion), the scales used in the study, and the use of sterile transparent film dressing. In the experimental group, a sterile transparent film dressing was used to fix the catheter and was monitored hourly until the catheter was removed. The infiltration scale for infants, , the criteria of extravasation (Redness accompanied by a vesicle, tissue necrosis, and ulcer), and The Phlebitis Scale were used to evaluate the catheter site.
Study: NCT01082770

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEGO
Description: A bung that can be attached to the end of dialysis lines that can be directly attached to the dialysis machine with minimal handling

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard
Description: Patients in this group will have a normal 'bung' placed at the end of their dialysis line, which will need to be removed by nursing staff prior to initiation of dialysis
Study: NCT03766789

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cell phone application
Description: cell phone to organize medications
Study: NCT04444817

Intervention type: DRUG
Intervention: Tacrolimus
Description: Similar to the clinical routine, as soon as a patient is able to swallow and has a sufficient gastrointestinal activity, Tacrolimus-based immunosuppression using Prograf®, Advagraf® or Envarsus® will be started. Furthermore, calcineurin inhibitors-based immunosuppression will be used (initial dose based on the patients' body weight) with the goal of tough levels of 3-7 ng/mL in the first seven days after liver transplantion, depending on immune status and indication for transplantation. Further tough levels will be determined based on factors such as patients' history and indication for liver transplant.
Study: NCT04372017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Participants randomized to placebo will take IU1600 on day 1 and IU 800 on days 2-5.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Participants randomized to placebo will take IU1600 on day 1 and IU 800 on days 2-5.
Study: NCT03433079

Intervention type: DIAGNOSTIC_TEST
Intervention: Myoglobin
Description: The level of myoglobin was assessed in all patients.
Study: NCT01737554

Intervention type: OTHER
Intervention: Catheter Resistance Monitoring
Description: Weekly measurement of resistance to flow in the lumen(s) of a CVAD with the commercially available Alaris® Syringe Module IV pump. The aim is to identify an increase in resistance greater than normal variation. Inline pressure measurements will be recorded at multiple flow-rates and resistance will be estimated from the gradient of the pressure-flow curve.
Study: NCT03497936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women's Stories
Description: Women's Stories is a brief, HPV vaccination promotion intervention. It presents vaccine information and videos of HPV vaccine decision making. It also includes follow up vaccine reminder text messages.
Study: NCT02666781

Intervention type: OTHER
Intervention: ApneaLink Plus, BIA Device
Description: The study is only observational. No interventions will be performed. ApneaLink Plus will be used to diagnose Obstructive Sleep Apnea in potential candidates and grade its severity on Postoperative night 2 in participants. A BIA Device will be used to detect segmental fluid shifts. A 3-D accelerometer will be used to detect head and neck position.
Study: NCT03224208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle
Study: NCT00688116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA 9090 (ganetespib)
Description: This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 (ganetespib) during a 1-hour infusion 2 times per week (e.g., \[Monday, Thursday\] or \[Tuesday, Friday\]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.
Study: NCT00627393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard antimicrobial therapy
Description: Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard antimicrobial therapy
Description: Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions
Description: Participants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10\^10 per collection (or proportionately less for participants less than 30 kg in weight).

Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF/dexamethasone
Description: Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.

Intervention type: DEVICE
Group type: OTHER
Intervention: Apheresis machine
Description: Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.
Study: NCT03513770

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wrist-to-elbow (W-E) occlusion
Description: An IV will be inserted in the antecubital fossa of one arm. The arm will be fitted with occlusion cuffs arranged in a continuous fashion from the wrist to the elbow. A final cuff will be placed on the upper arm. The cuffs from the wrist to the elbow will be inflated to the same pressure of up to 300 mmHg using a pressurized air tank.~First, the subject?s arm will be elevated and the subject will make a fist to squeeze blood from the hand. Then the wrist cuff will be inflated. Once that cuff is fully inflated, the next cuff in the sequence will be inflated. Cuffs are inflated in sequence until the elbow cuff is inflated. After a 10-15 second period to allow blood to drain, the upper arm cuff will inflate (up to 250 mmHg) to keep any additional blood from entering the forearm. Next, the cuffs on the forearm will be removed but the upper arm cuff will remain inflated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrist-to-elbow (W-E) occlusion
Description: An IV will be inserted in the antecubital fossa of one arm. The arm will be fitted with occlusion cuffs arranged in a continuous fashion from the wrist to the elbow. A final cuff will be placed on the upper arm. The cuffs from the wrist to the elbow will be inflated to the same pressure of up to 300 mmHg using a pressurized air tank.~First, the subject?s arm will be elevated and the subject will make a fist to squeeze blood from the hand. Then the wrist cuff will be inflated. Once that cuff is fully inflated, the next cuff in the sequence will be inflated. Cuffs are inflated in sequence until the elbow cuff is inflated. After a 10-15 second period to allow blood to drain, the upper arm cuff will inflate (up to 250 mmHg) to keep any additional blood from entering the forearm. Next, the cuffs on the forearm will be removed but the upper arm cuff will remain inflated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine
Description: In the COX blockade trial, just after the Wrist-to-elbow occlusion, 6 mg ketorolac tromethamine in 10 ml saline will be infused into the forearm over 1 minute. After 10 minutes, a second infusion of ketorolac tromethamine (up to 3 mg) in 5% of the forearm volume of saline,( \~40-60 ml) will be infused into the occluded forearm at a rate of \~ 30 ml/min. Five minutes of data will then be collected before releasing the upper arm cuff. Infusion 1 is to block the COX pathway, while infusion 2 is to induce venous distension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline control
Description: In the saline control trial performed on a separate day, saline (without ketorolac) in identical volumes as those in the COX blockade trial, will be infused.
Study: NCT03088696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stimulation
Description: activation of the acupuncture point

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no stimulation
Description: no activation of the acupuncture point
Study: NCT00593346

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: brachytherapy (radioactive implants)
Study: NCT02954536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin may be administered instead, at a dose of 130 mg/m2/day as an I.V.over approximately 2 hours on Day 1 every 21-day cycles, up to a maximum of 8 cycles in the absence of disease progression or until other withdrawl criteria are met. Patients may begin with reduced dose of oxaliplatin 104 mg/m2 as starting dose if deemed necessary per the treating physician discretion. Oxaliplatin will be administered after the completion of the pembrolizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Only for patients unable to take oral medications (because of certain circumstances such as malabsorption, difficulty swallowing, or other conditions that could affect intake of oral capecitabine medication), 5-FU may be administered instead, at a dose of 800 mg/m2/day as a continuous infusion over 5 days (Day 1 to Day 5 of each cycle), every 21 days. This decision should be made prior to registration by the treating physician; switching from capecitabine to 5-FU, or vice versa, will not be allowed during the study. 5-FU will be administered after completion of the cisplatin infusion.
Study: NCT01064388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9742
Description: IV infusion, 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion, 15 days
Study: NCT03792633

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19
Description: huCART19 infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19
Description: huCART19 infusion
Study: NCT02818959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JenaValve Pericardial TAVR System
Description: The JenaValve Pericardial TAVI system is intended for use in subjects with symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.
Study: NCT04428073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covax-19™
Description: Therapeutic vaccine for SARS-CoV-2 infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covax-19™
Description: Therapeutic vaccine for SARS-CoV-2 infection
Study: NCT02306330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Malditof
Description: Malditof MS system is applied for Malditof group for identifying pathogens. It takes 20 minutes to give the results.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine clinical microbiology
Description: Pathogens will be identified by the routine clinical microbiology of the hospital.
Study: NCT04281290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy - electroporation with Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
Description: Procedure: Electrochemotherapy Exploration, anesthesia, pancreatic cancer resection, bleomycin administration, electroporation, formation of all anastomoses.~Device: Cliniporator Vitae® Positioning of plate electrodes according to landmarks, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization, approximately 1000V/cm), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization.~Drug: Bleomycin PHC 15 e. (United States Pharmacopeia - USP) Intravenous bolus administration of bleomycin (15 mg/m2)
Study: NCT01359488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRS-317
Description: VRS-317 Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRS-317
Description: VRS-317 Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRS-317
Description: VRS-317 Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRS-317
Description: VRS-317 Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRS-317
Description: VRS-317 Single dose
Study: NCT02803788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramosetron, ondansetron, dexamethasone
Description: prevention of post-operative nausea vomiting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron, ondansetron, dexamethasone
Description: prevention of post-operative nausea vomiting
Study: NCT00521079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy ON
Description: Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Therapy OFF
Description: Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)
Study: NCT02524327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toolbox: Automated group
Description: A dedicated algorithm controls the infusion rate of drugs depending on the magnitude of variation of the bispectral index

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual group
Description: The anesthesiologist controls the infusion rate of drugs depending of the magnitude of variation of the bispectral index
Study: NCT00706368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point of care tests
Description: Several point-of-care tests are offered: OSOM TV rapid trichomonas test; OSOM BV Blue rapid test; pHEMalert vaginal pH test. All subjects receive the OSOM TV test, while the other two are optional.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point of care tests
Description: Several point-of-care tests are offered: OSOM TV rapid trichomonas test; OSOM BV Blue rapid test; pHEMalert vaginal pH test. All subjects receive the OSOM TV test, while the other two are optional.
Study: NCT04552951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Single doe of 100.000 IU
Study: NCT02121223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: post-dilatation with a Quantum Maverick balloon
Description: post-dilatation with a Quantum Maverick balloon at high pressure (\>=16atm) for at least 15 seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: manual thrombus aspiration + Promus Element stent implant
Description: manual thrombus aspiration followed by Promus Element stent implantation at normal pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manual thrombus aspiration + Promus Element stent implant
Description: manual thrombus aspiration followed by Promus Element stent implantation at normal pressure
Study: NCT04426422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: treated with metformin 1500-2000mg daily
Study: NCT02333435

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA
Description: 3g/day of purified EPA , capsules, taken once daily, for 14 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3g/day of placebo (high oleic sunflower oil) , capsules, taken once daily, for 14 months
Study: NCT02649166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: The deep brain stimulation system includes an implantable neurostimulator, thalamic leads to be implanted in the ventral intermediate nucleus (Vim), and subdural cortical strips. The deep brain stimulation system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for deep brain stimulation. At 6 months, the investigators will determine whether or not the subject is a candidate for closed-loop deep brain stimulation. Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. These subjects will been seen every 6 months for evaluation as part of normal clinical care for deep brain stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop deep brain stimulation
Description: The deep brain stimulation system includes an implantable neurostimulator, Vim thalamic leads, and subdural strips. Six months post-surgery, the deep brain stimulation system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for deep brain stimulation. Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
Study: NCT00397501

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: Trastuzamab, 6mg/kg, within 48 hrs before BBBD~Then, Trastuzumab, 2mg/kg, weekly until next BBBD Then continue for 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: 200mg/m2/day x 2 days; total dose 400mg/m2 Infused i.a. over 10 mins in 200ml of normal saline after MTX infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: 200mg/m2/day x 2 days; total dose 400mg/m2 Infused i.a. over 10 mins in 200ml of normal saline after MTX infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium thiosulfate
Description: STS dose admin i.v. over 15mins @ 4hrs post carboplatin = 20gm/m2; STS dose admin i.v. over 15mins @ 8hrs post carboplatin = 16gm/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium thiosulfate
Description: STS dose admin i.v. over 15mins @ 4hrs post carboplatin = 20gm/m2; STS dose admin i.v. over 15mins @ 8hrs post carboplatin = 16gm/m2
Study: NCT03807986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanofat grafting
Description: Nanofat grafting will be applied once every three months for 2 times.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfat grafting
Description: Microfat grafting will be applied once every three months for 2 times.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) Injection
Description: PRP Injection will be applied once a month for 6 times.
Study: NCT02850484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Inhaled corticosteroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Inhaled corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhaled corticosteroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Long Acting Beta Agonist (LABA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Long Acting Beta Agonist (LABA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Long Acting Beta Agonist (LABA)
Study: NCT03046693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A Citicoline 1000 mg oral tablet
Description: Citicoline 1000 mg will be repackaged and given to Group A for 60 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group B placebo oral tablet
Description: Placebo will be repackaged and given to Group B for 60 days
Study: NCT00714545

Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: Intracoronary brachytherapy
Description: Beta irradiation with a 40-mm strontium/lytrium-90 source
Study: NCT03807986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) Injection
Description: PRP Injection will be applied once a month for 6 times.